相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression
Filippo Cantu et al.
JOURNAL OF AFFECTIVE DISORDERS (2021)
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
Katharine Dunlop et al.
NEUROPSYCHOPHARMACOLOGY (2020)
One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials
Fredrik Hieronymus et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report
Rudolf Uher et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder
Sidney H. Kennedy et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Sidney H. Kennedy et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2016)
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
Sidney H. Kennedy et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design
Madhukar H. Trivedi et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2016)
Assessing anhedonia in depression: Potentials and pitfalls
Sakina J. Rizvi et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2016)
Scaling-up treatment of depression and anxiety: a global return on investment analysis
Dan Chisholm et al.
LANCET PSYCHIATRY (2016)
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability
Larry Culpepper et al.
AMERICAN JOURNAL OF MEDICINE (2015)
Measuring anhedonia: impaired ability to pursue, experience, and learn about reward
Kristine Romer Thomsen
FRONTIERS IN PSYCHOLOGY (2015)
The motivation and pleasure dimension of negative symptoms: Neural substrates and behavioral outputs
Ann M. Kring et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
The Impact of Individual Depressive Symptoms on Impairment of Psychosocial Functioning
Eiko I. Fried et al.
PLOS ONE (2014)
Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting
Jeremy Coplan et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms
R. Uher et al.
PSYCHOLOGICAL MEDICINE (2012)
Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study
H. J. Conradi et al.
PSYCHOLOGICAL MEDICINE (2011)
Antidepressant Monotherapy: A Claims Database Analysis of Treatment Changes and Treatment Duration
Dominique Milea et al.
CLINICAL THERAPEUTICS (2010)
Akathisia and second-generation antipsychotic drugs
Rajeev Kumar et al.
CURRENT OPINION IN PSYCHIATRY (2009)
The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research
Patrick E. McKnight et al.
CLINICAL PSYCHOLOGY REVIEW (2009)
How should remission from depression be defined? The depressed patient's perspective
M Zimmerman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression
AJ Rush et al.
BIOLOGICAL PSYCHIATRY (2003)
The PHQ-9 - Validity of a brief depression severity measure
K Kroenke et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2001)
分享论文
